Pages that link to "Q33960777"

The following pages link to Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response (Q33960777):

Displaying 43 items.

• A genomewide association study of citalopram response in major depressive disorder (Q24656746) (← links)
• The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key? (Q26741187) (← links)
• From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment (Q27015830) (← links)
• Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link? (Q28080944) (← links)
• Genetic prediction of antidepressant drug response and nonresponse in Korean patients (Q28543005) (← links)
• Chronic citalopram administration causes a sustained suppression of serotonin synthesis in the mouse forebrain (Q30487373) (← links)
• Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder (Q33913645) (← links)
• Pharmacogenetics of antidepressant response (Q34155796) (← links)
• Biomarkers to predict antidepressant response (Q34247513) (← links)
• Understanding the pharmacogenetics of selective serotonin reuptake inhibitors (Q34424865) (← links)
• The dawn of pediatric personalized therapeutics (Q34473137) (← links)
• Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders (Q34473840) (← links)
• Targeting tryptophan hydroxylase 2 in affective disorder (Q34623863) (← links)
• TPH1 A218C polymorphism and temperament in major depression (Q34676880) (← links)
• Personalized medicine in psychiatry: problems and promises (Q34726454) (← links)
• Resequencing DCDC5 in the Flanking Region of an LD‐SNP Derived from a Kidney‐Yang Deficiency Syndrome Family (Q35020300) (← links)
• Pharmacogenetics of antidepressants (Q35026088) (← links)
• Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response (Q35040545) (← links)
• No effect of serotoninergic gene variants on response to interpersonal counseling and antidepressants in major depression (Q36941592) (← links)
• Pharmacogenetics studies in STAR*D: strengths, limitations, and results (Q37178537) (← links)
• Brain plasticity and genetic factors (Q37594329) (← links)
• Genetic Influences on Neural Plasticity (Q37822563) (← links)
• Pharmacogenetics of antidepressant drugs: current clinical practice and future directions (Q37989490) (← links)
• Do we need pharmacogenetics to personalize antidepressant therapy? (Q38070163) (← links)
• Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research (Q38121519) (← links)
• Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy (Q38154911) (← links)
• Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications (Q38484370) (← links)
• Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks (Q38657429) (← links)
• Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response (Q38823641) (← links)
• Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies. (Q38983579) (← links)
• Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder (Q39422188) (← links)
• Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder (Q39696405) (← links)
• Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression (Q42785023) (← links)
• HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort (Q43236048) (← links)
• 5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system. (Q45902720) (← links)
• Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder (Q46821332) (← links)
• Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years (Q47666907) (← links)
• Association between tryptophan hydroxylase-2 genotype and the antidepressant effect of citalopram and paroxetine on immobility time in the forced swim test in mice (Q49093007) (← links)
• Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response (Q50786215) (← links)
• PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway (Q56972839) (← links)
• Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk (Q64249357) (← links)
• Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels (Q97649750) (← links)
• Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis (Q100958735) (← links)